GlassScriptPhysician profile
Mary Anderson
NPI 1083611057
$5,045.59
in general payments reported to CMS, 2019-2025
39 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $599 · 2021: $781 · 2022: $1,047 · 2023: $835 · 2024: $821 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.66 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $717.76 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $458.73 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $290.19 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $239.98 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.32 | 2019-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $234.47 | 2019-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.12 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $220.94 | 2019-2025 | Ozempic, Rybelsus |
| Upsher-Smith Laboratories LLC | $208.25 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $186.95 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $178.83 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $175.41 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $167.69 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $167.57 | 2019-2021 | |
| Mylan Specialty L.P. | $143.51 | 2019-2023 | Yupelri |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $132.81 | 2019-2022 | |
| Abbvie INC. | $126.16 | 2021-2024 | Vraylar |
| Lilly USA, LLC | $123.85 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $117.06 | 2022-2024 | Rexulti |
| Grifols USA, LLC | $112.25 | 2021-2024 | Prolastin-C Liquid |
| Idorsia Pharmaceuticals US INC | $76.84 | 2022-2024 | Quviviq |
| Allergan, INC. | $50.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $43.10 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $40.28 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $38.68 | 2021-2022 | |
| Abbott Laboratories | $35.52 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $34.15 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $30.71 | 2019-2020 | |
| Axsome Therapeutics, INC. | $29.72 | 2023 | Auvelity |
| Exact Sciences Corporation | $28.54 | 2023-2024 | Cologuard Collection Kit |
| Viatris Specialty LLC | $23.52 | 2025 | Yupelri |
| Daiichi Sankyo INC. | $22.92 | 2021 | |
| Ironshore Pharmaceuticals INC. | $21.31 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.23 | 2024 | Caplyta |
| Collegium Pharmaceutical, INC. | $16.73 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $16.67 | 2025 | Xelstrym, Secuado |
| Kyowa Kirin, INC. | $14.27 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2025 | Zoryve |
| Gilead Sciences, INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.